Parabilis Medicines, Inc. (PBLS)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
PBLS Chart
Parabilis Medicines, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Brian Baylis Bell Investment Advisors Inc. | 451 | $12,343.87 | $15,775.98 | $3,432.11 | 27.8% |
 Li Peng China Universal Asset Management Co. Ltd. | 1,600 | $43,792 | $54,368 | $10,576 | 24.15% |
 Yuen Man Lee Persistent Asset Partners Ltd. | 4,130 | $113,038 | $144,467.4 | $31,429.4 | 27.8% |
Parabilis Medicines, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TA Tazeen Ahmad B of A Securities | 1,518.75 | $44,630.76 | $48,539.11 | $3,908.35 | 8.76% |
Parabilis Medicines, Inc. (PBLS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Parabilis Medicines, Inc. ever had a stock split?
Parabilis Medicines, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mathai Mammen CEO | NASDAQ (NGS) Exchange | 698955101 CUSIP |
| US Country | 145 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Fog Pharmaceuticals, Inc. is a pioneering clinical-stage pharmaceutical company dedicated to the discovery and development of innovative therapies aimed at targeting and neutralizing cancer-causing proteins within cancer cells. The company specializes in a unique class of therapeutic molecules known as cell-penetrating miniproteins (CPMPs), designed for effective delivery deep into cell interiors where traditional therapies may struggle to operate. Founded in 2015 by a distinguished team of experts including Gregory L. Verdine, WeiQing Zhou, and David Philip Lane, Fog Pharmaceuticals is headquartered in the vibrant biotech hub of Cambridge, Massachusetts. The firm's focus on addressing the challenges presented by cancer biology is at the forefront of its mission, striving to transform the landscape of cancer treatment.
Products and Services
- Cell-Penetrating Miniproteins (CPMPs)
Fog Pharmaceuticals develops an innovative line of cell-penetrating miniproteins (CPMPs), which are designed to effectively penetrate cell membranes and target specific cancer-causing proteins. These miniproteins are engineered to reach and neutralize problematic proteins that contribute to cancer progression, providing a novel approach to treating various types of cancer.
- Targeted Cancer Therapeutics
The company is focused on creating targeted cancer therapeutics that modulate the activity of proteins implicated in cancer. This focused approach not only aims to improve the efficacy of cancer treatments but also seeks to minimize side effects often associated with traditional therapies by precisely targeting only the relevant cancer-associated proteins.
- Clinical Research and Development
Fog Pharmaceuticals invests in robust clinical research and development programs to bring its innovations from the laboratory to the clinic. This includes preclinical studies, clinical trials, and regulatory engagement to ensure that its therapeutic candidates advance appropriately through the drug development pipeline.
- Collaboration and Partnerships
The company actively seeks out collaborations with academic institutions, research organizations, and industry partners to enhance its scientific capabilities and expand its product pipeline. By leveraging external expertise and resources, Fog Pharmaceuticals aims to accelerate the development of effective cancer therapies.
- Consultative Services
In addition to its product offerings, Fog Pharmaceuticals provides consultative services to other biopharmaceutical companies. This includes expertise in miniprotein technology, cancer target validation, and strategic development plans for bringing new cancer therapies to market.
